Literature DB >> 599410

Blood and salivary concentrations of sulfamethoxazole and trimethoprim in man.

F B Eatman, A C Maggio, R Pocelinko, H G Boxenbaum, K A Geitner, W Glover, T Macasieb, A Holazo, R E Weinfeld, S A Kaplan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 599410     DOI： 10.1007/bf01059687

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN： 0090-466X


× No keyword cloud information.
  10 in total

1.  Concentrations of trimethoprim and sulphamethoxazole in aqueous humour and plasma from regimens of co-trimoxazole in man.

Authors:  J D Salmon; A S Fowle; A Bye
Journal:  J Antimicrob Chemother       Date:  1975-06       Impact factor: 5.790

2.  Trimethoprim-sulfamethoxazole in chronic bronchitis.

Authors:  G W Jordan; S F Krajden; P D Hoeprich; G A Wong; T H Peirce; D C Rausch
Journal:  Can Med Assoc J       Date:  1975-06-14       Impact factor: 8.262

3.  Trimethoprim in human saliva, bronchial secretion and lung tissue.

Authors:  I Hansen; M Lykkegaard Nielsen; S Bertelsen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1973

4.  Penetration of trimethoprim and sulphamethoxazole into the aqueous humour.

Authors:  P E Pohjanpelto; T J Sarmela; T Raines
Journal:  Br J Ophthalmol       Date:  1974-06       Impact factor: 4.638

5.  Pharmacokinetics of tolbutamide: prediction by concentration in saliva.

Authors:  S B Matin; S H Wan; J H Karam
Journal:  Clin Pharmacol Ther       Date:  1974-12       Impact factor: 6.875

6.  Antimicrobial substances in saliva: sulphamethoxazole and trimethoprim (co-trimoxazole).

Authors:  A A Quayle; D M Hailey
Journal:  Br J Oral Surg       Date:  1973-07

7.  The concentration of trimethoprim in prostatic fluid: nonionic diffusion or active transport?

Authors:  T A Stamey; S R Bushby; J Bragonje
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

8.  Semiautomated spectrophotofluorometric determination of trimethoprim in biological fluids.

Authors:  S A Kaplan; R E Weinfeld; T L Lee
Journal:  J Pharm Sci       Date:  1973-11       Impact factor: 3.534

9.  Prediction of antimeningococcic chemoprophylactic efficacy.

Authors:  P D Hoeprich
Journal:  J Infect Dis       Date:  1971-02       Impact factor: 5.226

10.  Proposed model for screening antimicrobial agents for potential use in eliminating meningococci from the nasopharynx of healthy carriers.

Authors:  L F Devine; R C Knowles; W E Pierce; R O Peckinpaugh; C R Hagerman; R I Lytle
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1968
  10 in total
  10 in total

1.  Engineering Reversible Cell-Cell Interactions with Lipid Anchored Prosthetic Receptors.

Authors:  Clifford M Csizmar; Jacob R Petersburg; Alex Hendricks; Lawrence A Stern; Benjamin J Hackel; Carston R Wagner
Journal:  Bioconjug Chem       Date:  2018-03-23       Impact factor: 4.774

Review 2.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

Review 3.  Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-06       Impact factor: 9.546

4.  Trimethoprim: prediction of serum concentrations from saliva measurements.

Authors:  I D Watson; M J Stewart
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole).

Authors:  R B Patel; P G Welling
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

6.  Serum and saliva levels of a trimethoprim-sulfamethopyrazine combination in man.

Authors:  A Sardi; M P Vettaro; R Alesina; S Grasso; G Meinardi; I de Carneri; V Tamassia
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

Review 7.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

8.  A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug-Drug-Gene Interaction Predictions.

Authors:  Denise Türk; Nina Hanke; Thorsten Lehr
Journal:  Pharmaceutics       Date:  2020-11-10       Impact factor: 6.321

9.  A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators.

Authors:  Yiting Yang; Zexin Zhang; Ping Li; Weimin Kong; Xiaodong Liu; Li Liu
Journal:  Pharmaceutics       Date:  2021-05-11       Impact factor: 6.321

10.  Pharmacokinetics of mefloquine and its effect on sulfamethoxazole and trimethoprim steady-state blood levels in intermittent preventive treatment (IPTp) of pregnant HIV-infected women in Kenya.

Authors:  Michael Green; Kephas Otieno; Abraham Katana; Laurence Slutsker; Simon Kariuki; Peter Ouma; Raquel González; Clara Menendez; Feiko ter Kuile; Meghna Desai
Journal:  Malar J       Date:  2016-01-05       Impact factor: 2.979
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.